Professor Gareth Evans leads the Prevent Breast Cancer genetic research team. He is particularly interested in biomarkers of risk of developing breast cancer.
Professor Evans has established a national and international reputation in clinical and research aspects of cancer genetics, particularly in neurofibromatosis and breast cancer. He has developed a clinical service for cancer genetics in the North West Region of England, which is nationally regarded. He is an important opinion leader nationally through membership of committees and was chairman of the NICE Familial Breast Cancer Guideline Development Group (2002-2010) and is now clinical lead (2011-).
He lectures throughout the UK and internationally on hereditary breast cancer and cancer syndromes. He has given plenary lectures at many international meetings including the International Congress of Human Genetics and two invited lecture tours across Australia (1995, 2001). He has developed a national training program for clinicians, nurses and genetic counsellors in breast cancer genetics and established a system for risk assessment and counselling for breast cancer in Calman breast units implemented through a training course (1998-2011).
He has published 603 peer reviewed research publications; 225 as first or senior author. He has published over 90 reviews and chapters and has had a book published by Oxford University Press on familial cancer. He has an ISI web of knowledge H-index of 80 and a google scholar H-index of 108 having only published his first article in 1990. In the last 5 years he has raised over £10 million in grants for multicentre and local studies – approximately £5 million to Manchester. He is Chief Investigator on a £1.59 million NIHR program grant (2009-2014) on breast cancer risk prediction and also has an NIHR RfPB grant as CI (2011). He has led a successful bid for a Nationally funded NF2 service (£7.5 million pa) that started in 2010 and is involved in the national complex NF1 service.